POZEN — Merger or Acquisition (July 2015)
26 slides from POZEN's merger presentation, Jul 20, 2015
Slide 1: Strategic Rationale and Vision for Aralez Pharmaceuticals
“Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015
Slide 2: Forward-looking statements
This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equit
Slide 3: A Transformational Combination
A Transformational Combination World-Class Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Irish Domicile Offers Financial & Competitive Advantage 2 $150M at close ($75m equity/$75m convertible note) $200M commi
Slide 4: Aralez: Creating a Platform for Growth
Aralez: Creating a Platform for Growth Strong Balance Sheet Platform for Growth Diversified Revenue Streams and Portfolio Adrian Adams (CEO) and Andrew Koven (President & CBO) have track record of value creation Auxilium (Endo), Inspire (Merck), Sepracor (Dainippon Sumitomo) and Kos (Abbott) World C
Slide 5: Transaction Overview
Transaction Overview Structure POZEN and Tribute will each become wholly owned subsidiaries of Aralez Aralez will be an Irish plc Aralez shares are expected to trade on Nasdaq and the TSX upon closing Exchange Ratio POZEN: 1.000 share of Aralez for each share of POZEN Tribute: 0.1455 share of Aralez
Slide 6: IPOZEN
IPOZEN™ Transforming medicine. Transforming lives.
Slide 7: YOSPRALA: Significant Commercial Opportunity
YOSPRALA: Significant Commercial Opportunity 24 MM* secondary prevention patients in US Differentiation: Coordinated Delivery of Aspirin and Omeprazole differentiated from commercially available components Convenience vs. taking two separate products Planning patient affordable pricing strategy Opp
Slide 8: YOSPRALA: Significant Commercial Opportunity
YOSPRALA: Significant Commercial Opportunity Expand investment over time as YOSPRALA gains traction with prescribers and patients Launch with ~110 sales professionals, targeting top 20% of secondary prevention specialist (CV and IM) physicians Over time invest into opportunity; expand to 300 sales p
Slide 9: YOSPRALA: Regulatory Status
US: PA32540/PA8140 NDA filing 505b(2) application Proposed label for secondary prevention of CVD per aspirin monograph (excluding acute MI) API aspirin manufacturer appears on track with corrective actions that FDA has deemed acceptable pending verification Continuing to pursue alternate supplier fo
Slide 10: YOSPRALA and MT400: Canadian Opportunity
YOSPRALA and MT400: Canadian Opportunity Opportunity Selected Market Research Timing Tracking Heart Disease & Stroke in Canada – June 2009; 4.8% Heart Disease ;1.1% Stroke (Public Health Agency of Canada; www.publichealth.gc.ca ** Praxis Yosprala Acceptance Study, April 2015, 403 physicians and 494
Slide 11: YOSPRALA: Protected by a Robust Patent Position
‘A pharmaceutical composition in unit dosage form comprising an enteric-coated NSAID and a non-enteric-coated acid inhibitor formulated for coordinated release’ CA 2 449 098 C (expires 5/31/2022) Counterpart upheld by EPO Opposition Division 12/12/2012 Also issued: Australia, Eurasia, Israel, Japan,
Slide 12: Tribute
(TRIBUTE y
Slide 13: Tribute: Compelling Canadian Growth Story
Tribute: Compelling Canadian Growth Story Tribute is a Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and promotion of Canadian and US healthcare products Sales force of 24 sales representatives across Canada 20 primary care (PCPs/GPs, neurologists, derm
Slide 14: Fibricor
Indications Severe Hypertriglyceridemia Primary Hypercholesterolemia or Mixed Dyslipidemia Unique fenofibric acid formulation competes in the US$2.5 billion triglyceride lowering medication market Protected by 4 separate patents valid until August 20, 2027 Product sales of approximately US$4.7 milli
Slide 15: Bezalip SR
Bezalip SR Well established with 25 years of therapeutic use globally and approved in 40 countries Modified-release tablet that contains the active ingredient bezafibrate Once-a-day dosing designed to release slowly and continuously Helps lower LDL-C and triglycerides while raising HDL-C Improves in
Slide 16: CAMBIA
CAMBIA Only prescription NSAID available and approved for the acute treatment of migraine attached with or without aura in adults 18 years of age or older New patented, water soluble, buffered powder formulation designed to deliver a 50mg dose when mixed with water Fast migraine pain relief Adverse
Slide 17: Tribute Acquisition of Medical Futures Inc.
Tribute Acquisition of Medical Futures Inc. 13 marketed products and 2 pipeline products Total purchase price + Cdn$25 million $6 million cash contingent milestones (anticipated within 90 days) Cdn$1.25 million milestone on approval of Octasa in Canada Cdn$1.25 million on approval of Bedbugz in Cana
Slide 18: Attractive Financial Profile
Attractive Financial Profile $75M equity Robust balance sheet and demonstrated access to capital $75M convertible debt 2.5% with 32.5% premium $200M credit facility For future acquisitions Strong projected revenue growth(1) (1) Figures reflect the addition of standalone projections and do not includ
Slide 19: Attractive Value Creation for Shareholders
Attractive Value Creation for Shareholders Potential revenue synergies through existing infrastructures Canadian Infrastructure: Leverage to commercialize Pozen’s products, if approved, including YOSPRALA and MT400 US Infrastructure: Build to commercialize Fibricor and, if approved, Yosprala and Bez
Slide 20: The Aralez Growth Strategy & Priorities
The Aralez Growth Strategy & Priorities Maximize the value of expanded portfolio & geographic footprint Build around a cardiovascular-based, North American-focused portfolio Aggressive approach to CD&L and M&A to drive growth supported by new platform Leverage platform for growth with tax-efficient
Slide 21: Strategic Rationale and Vision for Aralez Pharmaceuticals
“Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015
Slide 22: Back-Up Slides
Back-Up Slides
Slide 23: World Class Management Team with Proven Track Record
World Class Management Team with Proven Track Record of Successfully Growing Companies Kos Pharmaceuticals: Licensed NIASPAN and ADVICOR to Oryx in Canada Licensed NIASPAN and ADVICOR to Merck KGa in Europe Co-Promotion with Takeda for NIASPAN in US Co-Promotion with Barr Laboratories for NIASPAN in
Slide 24: YOSPRALA Reduces Gastric Damage vs. EC Aspirin in Proof-of-Concept Trials
YOSPRALA Consistently and Significantly Reduces Gastric Damage vs. EC Aspirin in Proof-of-Concept Trials Lanza Grading 0 = no visible lesions; 1 = 1 lesion; 2 = 2-10 lesions; 3 = 11-25 lesions; 4 = >25 lesions or an ulcer Methods Pooled results of POZEN studies (PA32520-101, -102, and -106) plus PA8
Slide 25: Complementary Products & Pipeline
Cardiovascular Pain Other Specialty Products Complementary Products & Pipeline MT400 Subject to approval in referenced market. Bezalip SR is approved in Canada but not approved in the United States. Treximet and VIMOVO are marketed by commercial partners of POZEN. VIMOVO is marketed outside of North
Slide 26: Medical Futures Inc. Products
Medical Futures Inc. Products